Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial

Table 2 Incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis

Variable	Naproxen1	Placebo2
Sex
Female	9/12b	19/28
Male	3/12	9/28
Age (yr)
< 40	5/12	10/28
> 40	7/12	18/28
Sphincterotomy
Yes	8/129	23/119
No	4/33	5/43
Precut required	2/31	2/31
Pancreatic duct injection
Yes	6/75b	23/84
No	6/82	5/83
Pancreatic duct cannulations
≥ 3	2/6b	10/23
≤ 2	3/6	14/23
ERCP duration (min)
> 40	4/12b	12/28
< 40	8/12	16/28
Biliary duct injection
Yes	9/134	24/135
No	3/23	4/25

¹Pancreatitis/naproxen (12/162, 7.4%);

²Pancreatitis/placebo (28/162, 17%).

^bP < 0.01 vs Placebo.